Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Financial Statements for the Nine Months Ended December 31, 2022 [IFRS] (Consolidated)

February 6, 2023

Company name: JMDC Inc.
Listing: Tokyo Stock Exchange
Stock code: 4483
URL: https://www.jmdc.co.jp/en/
Representative: Yosuke Matsushima, President and CEO
Inquiries: Yuta Yamamoto, Vice President and CFO
TEL: +81-3-5733-5010

Scheduled date to file quarterly securities report: February 14, 2023
Scheduled date to commence dividend payments: –
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results presentation meeting: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the first nine months of the fiscal year ending March 31, 2023 (from April 1, 2022 to December 31, 2022)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2022	19,542	24.6	4,028	18.3	4,007	18.0	2,655	16.9
December 31, 2021	15,679	35.1	3,405	40.5	3,396	41.1	2,271	43.9

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Nine months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
December 31, 2022	2,654	16.8	2,659	17.0	44.98	42.66
December 31, 2021	2,272	44.0	2,271	44.0	40.46	38.14

Reference: EBITDA Nine months ended December 31, 2022 ¥5,332 million [16.4%]
Nine months ended December 31, 2021 ¥4,580 million [39.5%]

Notes: 1. EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
2. During the nine months ended December 31, 2022, the Company finalized the provisional accounting treatment for business combinations. As a result, figures for the nine months ended December 31, 2021 reflect the finalization of the provisional accounting treatment.

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
As of	Millions of yen	Millions of yen	Millions of yen	%
December 31, 2022	95,138	62,857	62,877	66.1
March 31, 2022	62,053	31,165	31,170	50.2

Note: During the nine months ended December 31, 2022, the Company finalized the provisional accounting treatment for business combinations. As a result, figures as of March 31, 2022 reflect the finalization of the provisional accounting treatment.

2. Cash dividends

	Annual dividends				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2022	–	0.00	–	10.00	10.00
Fiscal year ending March 31, 2023	–	0.00	–		
Fiscal year ending March 31, 2023 (Forecast)				–	–

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecasts for the fiscal year ending March 31, 2023 (from April 1, 2022 to March 31, 2023)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2023	27,500	26.1	6,000	25.4	6,000	25.8	4,000	23.4	4,000	23.2	69.73

Note: Revisions to the earnings forecasts most recently announced: None

Reference: EBITDA Fiscal year ending March 31, 2023 (Forecast) ¥8,000 million [24.8%]

*** Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at end of the period (including treasury shares)

As of December 31, 2022	62,836,208 shares
As of March 31, 2022	56,514,208 shares

(ii) Number of treasury shares at end of the period

As of December 31, 2022	529 shares
As of March 31, 2022	497 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

For the nine months ended December 31, 2022	59,016,779 shares
For the nine months ended December 31, 2021	56,167,660 shares

*** Quarterly financial results reports are exempt from quarterly reviews conducted by certified public accountants or an audit corporation.**

*** Proper use of earnings forecasts, and other special items**

Notes on forward-looking statements

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to page 5 of the attached materials.

How to obtain supplementary documents on financial results

Supplementary documents on financial results are released via TDnet on the same day.

Attached Material Index

1. Qualitative information regarding financial results for the nine months ended December 31, 2022 2
(1) Explanation of operating results 2
(2) Explanation of financial position 4
(3) Explanation of consolidated earnings forecasts and other forward-looking statements 5
2. Condensed quarterly consolidated financial statements and significant notes thereto 6
(1) Condensed quarterly consolidated statement of financial position 6
(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income 7
(3) Condensed quarterly consolidated statement of changes in equity 9
(4) Condensed quarterly consolidated statement of cash flows 11
(5) Notes to condensed quarterly consolidated financial statements 12
Notes on going concern assumption 12
Segment information 12
Significant subsequent events 13

1. Qualitative information regarding financial results for the nine months ended December 31, 2022

(1) Explanation of operating results

JMDC Inc. (the "Company") is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.

In the Healthcare-Big Data segment, to promote the health services for payers, centered on health insurance associations, we provide analysis services for data held by payers as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.

In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.

In the Dispensing Pharmacy Support segment, we develop and sell systems such as receipt computers and electronic medication history systems to health insurance pharmacies, and also conduct tests of our own systems as we operate our own dispensing pharmacies.

Operating results for the nine months ended December 31, 2022 are as follows.

(Operating results)

(Millions of yen)

Category	9th fiscal year Nine months ended December 31, 2021		10th fiscal year Nine months ended December 31, 2022		YoY change	
Revenue	15,679		19,542		3,863	24.6%
Operating profit	3,405		4,028		623	18.3%
EBITDA [Margin]	4,580	[29.2%]	5,332	[27.3%]	751	16.4%

(Segment results)

(Millions of yen)

Category		9th fiscal year Nine months ended December 31, 2021		10th fiscal year Nine months ended December 31, 2022		YoY change	
Healthcare-Big Data	Segment revenue	9,883		13,144		3,260	33.0%
	Segment profit [ratio]	3,412	[34.5%]	4,022	[30.6%]	609	17.9%
Tele-medicine	Segment revenue	3,370		3,799		428	12.7%
	Segment profit [ratio]	1,200	[35.6%]	1,416	[37.3%]	216	18.0%
Dispensing Pharmacy Support	Segment revenue	2,567		2,788		220	8.6%
	Segment profit [ratio]	209	[8.2%]	310	[11.1%]	101	48.2%
Adjustment	Segment revenue	(143)		(189)		(46)	–
	Segment profit	(242)		(417)		(174)	–
Total	Revenue	15,679		19,542		3,863	24.6%
	EBITDA [margin]	4,580	[29.2%]	5,332	[27.3%]	751	16.4%

(Note) EBITDA is an objective indicator for judging the achievement of the JMDC Group's (the "Group's") management policies and strategies or management objectives. The Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to assess the Group's performance more effectively. The formulas for calculating EBITDA and EBITDA margin are as follows.

- EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- EBITDA margin: EBITDA / Revenue x 100

Healthcare-Big Data

The Group possesses the largest scale of healthcare big data in Japan that is available for public through data anonymization of receipts (admitted patients, day patients, prescriptions), medical examinations and member records received from health insurance associations. During the nine months ended December 31, 2022, the number of contracted health insurance associations and the annual transaction value per customer at pharmaceutical and insurance companies which the Company uses and utilizes, each continued to increase on a year-on-year basis, and the business is continuing to expand.

Moreover, the PepUp health information platform developed by the Company is used to generate individualized advice and display risk of diseases for every individual user based on the above healthcare-big data. The number of IDs issued for PepUp continued to expand during the nine months ended December 31, 2022.

In addition to the above business expansion, the Company significantly expanded its data originating from medical institutions by making Real World Data Co., Ltd. its subsidiary in July 2022, etc., and started initiatives to provide services in new areas such as clinical trials, etc.

Furthermore, the Company commenced joint research with LayerX Inc. into data privacy protection. Through this, the Company aims to be able to explain data anonymity for the fields of medical treatment and health provided to third parties based on even mathematical data while improving both the efficiency of processes carried out to preserve anonymity and the usefulness of the data.

During the nine months ended December 31, 2022, various negative factors such as the curtailment of face-to-face sales due to the spread of the novel coronavirus disease (COVID-19) continued. However, the business continued to expand.

As a result, segment revenue for the nine months ended December 31, 2022 was ¥13,144 million and segment profit (segment EBITDA) was ¥4,022 million.

Tele-medicine

The Group has the biggest platform for radiologists in Japan. During the nine months ended December 31, 2022, although the impact of a decrease in diagnostic imaging requests per medical institution due to the voluntary refraining from visiting hospitals as a result of the spread of COVID-19 continued, there were signs of recovery year on year, and revenue increased on a year-on-year basis as a result of the increase in the number of medical institutions utilizing remote image interpretation services.

We continue to take measures to expand our business, including adding functions to “AI-RAD,” an artificial intelligence engine platform that assists in diagnostic imaging, and preparations for full-scale business development in China.

As a result, segment revenue for the nine months ended December 31, 2022 was ¥3,799 million and segment profit (segment EBITDA) was ¥1,416 million.

Dispensing Pharmacy Support

During the nine months ended December 31, 2022, we worked to cultivate new customers while securing replacement demand from existing customers. Although the Group continued to be affected by a decline in sales at its own dispensing pharmacies and investment constraints at client dispensing pharmacies due to people refraining from visiting medical agencies, which will in turn reduce the number of times they visit dispensing pharmacies as a result of the spread of COVID-19, sales increased on a year-on-year basis affected by the addition of a former competitor to the Group during the first quarter of the previous fiscal year.

As a result, segment revenue for the nine months ended December 31, 2022 was ¥2,788 million and segment profit (segment EBITDA) was ¥310 million.

As a result of the above, for the nine months ended December 31, 2022, revenue increased to ¥19,542 million, operating profit to ¥4,028 million, and EBITDA to ¥5,332 million. Adjustments to reconcile EBITDA to operating profit are as follows.

(Reconciliation of EBITDA to operating profit)

(Millions of yen)

	9th fiscal year Nine months ended December 31, 2021	10th fiscal year Nine months ended December 31, 2022
EBITDA	4,580	5,332
Depreciation and amortization	(1,191)	(1,487)
Other income	47	203
Other expenses	(31)	(18)
Operating profit	3,405	4,028

(2) Explanation of financial position

(i) Assets, liabilities and equity

Assets

Assets at the end of the third quarter under review were ¥95,138 million, an increase of ¥33,085 million compared with the end of the fiscal year ended March 31, 2022. This was primarily due to an increase of ¥8,561 million in cash and cash equivalents as a result of the issuance of new shares through an international offering and the issuance of new shares through third-party allotment for OMRON Corporation, in addition to an increase of ¥19,832 million in goodwill due to the acquisition of the shares of Real World Data Co., Ltd. (subsidiary acquisition), etc.

Liabilities

Liabilities at the end of the third quarter under review were ¥32,281 million, an increase of ¥1,393 million compared with the end of the fiscal year ended March 31, 2022. Although ¥19,330 million in borrowing of funds was taken out in July 2022 to purchase multiple shares, some of which had already been purchased, the full amount was repaid in November of that year.

Equity

Equity at the end of the third quarter under review was ¥62,857 million, an increase of ¥31,691 million compared with the end of the fiscal year ended March 31, 2022. This was primarily due to an increase of ¥2,092 million in retained earnings due to the recording of ¥2,655 million in profit, ¥565 million in dividends paid, etc., in addition to increases of ¥14,888 million and ¥14,714 million in share capital and capital surplus, respectively, as a result of the issuance of new shares through an international offering and the issuance of new shares through third-party allotment for OMRON Corporation, etc.

(ii) Cash flows

Cash and cash equivalents (“cash”) at the end of the third quarter under review was ¥21,754 million, an increase of ¥8,562 million compared with the end of the fiscal year ended March 31, 2022.

The respective cash flow positions for the nine months ended December 31, 2022, and the factors thereof are as follows.

Cash flows from operating activities

During the nine months ended December 31, 2022, profit before tax was ¥4,007 million, an increase of ¥611 million on a year-on-year basis. Other inflows included depreciation and amortization of ¥1,487 million. At the same time, there were outflows of ¥588 million from an increase in trade and other receivables and ¥1,818 million from recording income taxes paid. As a result, net cash provided by operating activities was ¥2,490 million.

Cash flows from investing activities

Net cash used in investing activities was ¥21,803 million. This was primarily due to purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥19,213 million and purchase of property, plant and equipment of ¥1,192 million.

Cash flows from financing activities

Net cash provided by financing activities was ¥27,874 million. This was primarily due to the recording of ¥29,212 million in proceeds from issuance of shares as a result of the issuance of new shares through an international offering and the issuance of new shares through third-party allotment for OMRON Corporation, despite the recording of ¥564 million in dividends paid. Note that although ¥19,330 million in borrowing of funds was taken out in July 2022 to purchase multiple shares, some of which had already been purchased, the full amount was repaid in November of that year. These transactions are included in the proceeds from short-term borrowings and the repayments of short-term borrowings, respectively.

(3) Explanation of consolidated earnings forecasts and other forward-looking statements

As for the consolidated earnings forecasts, although the impact of the spread of COVID-19 continues to be unpredictable and there was also an impact on earnings from the new consolidation of Real World Data Co., Ltd., etc., the Company believes that these impacts on the Group will not cause earnings to deviate significantly from the initial forecast at this time. As a result, there is no change to the consolidated earnings forecasts stated in the “Summary of Financial Statements for the Fiscal Year Ended March 31, 2022” released on May 10, 2022.

2. Condensed quarterly consolidated financial statements and significant notes thereto

(1) Condensed quarterly consolidated statement of financial position

(Millions of yen)

	As of March 31, 2022	As of December 31, 2022
Assets		
Current assets		
Cash and cash equivalents	13,192	21,754
Trade and other receivables	9,283	10,282
Other financial assets	2,561	3,127
Inventories	248	326
Other current assets	693	748
Total current assets	25,979	36,240
Non-current assets		
Property, plant and equipment	8,420	10,661
Goodwill	19,169	39,001
Intangible assets	5,527	5,898
Other financial assets	1,298	1,616
Deferred tax assets	1,516	1,562
Other non-current assets	141	157
Total non-current assets	36,073	58,898
Total assets	62,053	95,138
Liabilities and equity		
Liabilities		
Current liabilities		
Borrowings	777	875
Trade and other payables	6,182	6,013
Lease liabilities	689	809
Income taxes payable	999	471
Contract liabilities	1,843	1,953
Other current liabilities	1,140	1,067
Total current liabilities	11,633	11,190
Non-current liabilities		
Borrowings	10,928	11,297
Lease liabilities	5,401	6,772
Retirement benefit liability	319	349
Provisions	276	463
Deferred tax liabilities	769	745
Contract liabilities	1,560	1,461
Total non-current liabilities	19,254	21,091
Total liabilities	30,887	32,281
Equity		
Share capital	9,091	23,980
Capital surplus	12,483	27,197
Treasury shares	(2)	(2)
Other components of equity	17	29
Retained earnings	9,580	11,672
Total equity attributable to owners of parent	31,170	62,877
Non-controlling interests	(5)	(19)
Total equity	31,165	62,857
Total liabilities and equity	62,053	95,138

(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income

Condensed quarterly consolidated statement of profit or loss

(Millions of yen)

	Nine months ended December 31, 2021	Nine months ended December 31, 2022
Revenue	15,679	19,542
Cost of sales	6,609	8,520
Gross profit	9,069	11,021
Selling, general and administrative expenses	5,680	7,177
Other income	47	203
Other expenses	31	18
Operating profit	3,405	4,028
Finance income	36	47
Finance costs	45	69
Profit before tax	3,396	4,007
Income tax expense	1,124	1,351
Profit	2,271	2,655
Profit attributable to		
Owners of parent	2,272	2,654
Non-controlling interests	(0)	0
Profit	2,271	2,655
Earnings per share		
Basic earnings per share (Yen)	40.46	44.98
Diluted earnings per share (Yen)	38.14	42.66

Condensed quarterly consolidated statement of comprehensive income

(Millions of yen)

	Nine months ended December 31, 2021	Nine months ended December 31, 2022
Profit	2,271	2,655
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	1	3
Total of items that will not be reclassified to profit or loss	1	3
Items that may be reclassified to profit or loss		
Foreign exchange differences on translation of foreign operations	(1)	0
Total of items that may be reclassified to profit or loss	(1)	0
Other comprehensive income, net of tax	(0)	3
Comprehensive income	2,271	2,659
Comprehensive income attributable to		
Owners of parent	2,272	2,658
Non-controlling interests	(0)	0
Comprehensive income	2,271	2,659

(3) Condensed quarterly consolidated statement of changes in equity

Nine months ended December 31, 2021 (from April 1 to December 31, 2021)

(Millions of yen)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2021	8,971	12,932	(1)	(2)	–	25
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	(1)	1	–
Total comprehensive income	–	–	–	(1)	1	–
Issuance of share acquisition rights	–	–	–	–	–	1
Share-based remuneration transactions	–	–	–	–	–	0
Exercise of share acquisition rights	98	89	–	–	–	(4)
Forfeiture of share acquisition rights	–	–	–	–	–	(0)
Purchase of treasury shares	–	–	(0)	–	–	–
Increase (decrease) by business combination	–	(560)	–	–	–	–
Transfer to retained earnings	–	–	–	–	(1)	–
Total transactions with owners	98	(471)	(0)	–	(1)	(3)
Balance as of December 31, 2021	9,070	12,461	(1)	(3)	–	22

	Equity attributable to owners of parent			Non-controlling interests	Total
	Other components of equity	Retained earnings	Total		
	Total				
Balance as of April 1, 2021	23	6,323	28,250	–	28,250
Profit	–	2,272	2,272	(0)	2,271
Other comprehensive income	(0)	–	(0)	–	(0)
Total comprehensive income	(0)	2,272	2,272	(0)	2,271
Issuance of share acquisition rights	1	–	1	–	1
Share-based remuneration transactions	0	–	0	–	0
Exercise of share acquisition rights	(4)	–	182	–	182
Forfeiture of share acquisition rights	(0)	–	(0)	–	(0)
Purchase of treasury shares	–	–	(0)	–	(0)
Increase (decrease) by business combination	–	–	(560)	0	(559)
Transfer to retained earnings	(1)	1	–	–	–
Total transactions with owners	(4)	1	(376)	0	(376)
Balance as of December 31, 2021	19	8,597	30,146	(0)	30,146

Nine months ended December 31, 2022 (from April 1 to December 31, 2022)

(Millions of yen)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2022	9,091	12,483	(2)	(4)	–	21
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	0	3	–
Total comprehensive income	–	–	–	0	3	–
Issuance of share acquisition rights	–	–	–	–	–	13
Exercise of share acquisition rights	155	155	–	–	–	(1)
Forfeiture of share acquisition rights	–	0	–	–	–	(0)
Issuance of new shares	14,732	14,558	–	–	–	–
Purchase of treasury shares	–	–	(0)	–	–	–
Dividends	–	–	–	–	–	–
Increase (decrease) by business combination	–	–	–	–	–	–
Transfer to retained earnings	–	–	–	–	(3)	–
Total transactions with owners	14,888	14,714	(0)	–	(3)	11
Balance as of December 31, 2022	23,980	27,197	(2)	(4)	–	33

	Equity attributable to owners of parent			Non-controlling interests	Total
	Other components of equity	Retained earnings	Total		
	Total				
Balance as of April 1, 2022	17	9,580	31,170	(5)	31,165
Profit	–	2,654	2,654	0	2,655
Other comprehensive income	3	–	3	–	3
Total comprehensive income	3	2,654	2,658	0	2,659
Issuance of share acquisition rights	13	–	13	–	13
Exercise of share acquisition rights	(1)	–	309	–	309
Forfeiture of share acquisition rights	(0)	–	–	–	–
Issuance of new shares	–	–	29,290	–	29,290
Purchase of treasury shares	–	–	(0)	–	(0)
Dividends	–	(565)	(565)	–	(565)
Increase (decrease) by business combination	–	–	–	(15)	(15)
Transfer to retained earnings	(3)	3	–	–	–
Total transactions with owners	8	(562)	29,048	(15)	29,032
Balance as of December 31, 2022	29	11,672	62,877	(19)	62,857

(4) Condensed quarterly consolidated statement of cash flows

(Millions of yen)

	Nine months ended December 31, 2021	Nine months ended December 31, 2022
Cash flows from operating activities		
Profit before tax	3,396	4,007
Depreciation and amortization	1,191	1,487
Decrease (increase) in trade and other receivables	(740)	(588)
Decrease (increase) in inventories	(42)	(58)
Increase (decrease) in trade and other payables	(31)	(424)
Other	(550)	(45)
Subtotal	3,222	4,378
Interest and dividends received	36	0
Interest paid	(43)	(68)
Income taxes paid	(1,332)	(1,818)
Net cash provided by (used in) operating activities	1,883	2,490
Cash flows from investing activities		
Purchase of property, plant and equipment	(258)	(1,192)
Purchase of intangible assets	(597)	(802)
Payments for loans receivable	(10)	(760)
Collection of loans receivable	–	110
Purchase of investments	(53)	(166)
Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation	–	25
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(4,327)	(19,213)
Other	(21)	195
Net cash provided by (used in) investing activities	(5,268)	(21,803)
Cash flows from financing activities		
Proceeds from short-term borrowings	–	19,330
Repayments of short-term borrowings	(2,622)	(19,543)
Proceeds from long-term borrowings	1,470	961
Repayments of long-term borrowings	(590)	(1,187)
Repayments of lease liabilities	(496)	(656)
Proceeds from issuance of shares	–	29,212
Proceeds from exercise of share acquisition rights	182	309
Dividends paid	–	(564)
Other	1	12
Net cash provided by (used in) financing activities	(2,055)	27,874
Net increase (decrease) in cash and cash equivalents	(5,439)	8,562
Cash and cash equivalents at beginning of period	19,898	13,192
Effect of exchange rate changes on cash and cash equivalents	0	(0)
Cash and cash equivalents at end of period	14,459	21,754

(5) Notes to condensed quarterly consolidated financial statements

Notes on going concern assumption

Not applicable.

Segment information

(1) Overview of reportable segments

The Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are regularly reviewed by the Board of Directors to make decisions about managerial resources to be allocated to the segments and assess their performances. The Group considers similarities in the nature of the services it provides and has three reportable segments: "Healthcare-Big Data," "Tele-medicine," and "Dispensing Pharmacy Support."

The main businesses and main services included in each reportable segment are as follows.

Reportable segments	Main businesses	Main services
Healthcare-Big Data	Business for industry Business for payers and individuals Business for medical service providers	Development and provision of medical databases (receipts, pharmaceuticals, etc.) and analysis of medical big data
Tele-medicine	Tele-medicine business	Remote image interpretation matching service and ASP service for remote image interpretation system
Dispensing Pharmacy Support	Dispensing pharmacy support business	Development and sales of business systems for dispensing pharmacies

(2) Information about reportable segments

Revenue and operating results by reportable segments of the Group are as follows.

Intersegment revenues are based on negotiated transaction prices, taking into account market prices and production costs. Segment profits are EBITDA (Operating profit + Depreciation and amortization ± Other income/expenses).

Figures for the nine months ended December 31, 2021 are the figures after retroactive revision due to the finalization of the provisional accounting treatment for business combinations.

Nine months ended December 31, 2021 (from April 1 to December 31, 2021)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare-Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	9,831	3,370	2,476	15,679	–	15,679
Intersegment revenue	52	–	90	143	(143)	–
Total	9,883	3,370	2,567	15,822	(143)	15,679
Segment profit EBITDA	3,412	1,200	209	4,823	(242)	4,580

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

Nine months ended December 31, 2022 (from April 1 to December 31, 2022)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare-Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	13,081	3,799	2,661	19,542	–	19,542
Intersegment revenue	62	–	127	189	(189)	–
Total	13,144	3,799	2,788	19,732	(189)	19,542
Segment profit EBITDA	4,022	1,416	310	5,749	(417)	5,332

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

A reconciliation of EBITDA to profit before tax is as follows.

(Millions of yen)

	Nine months ended December 31, 2021	Nine months ended December 31, 2022
EBITDA	4,580	5,332
Depreciation and amortization	(1,191)	(1,487)
Other income	47	203
Other expenses	(31)	(18)
Operating profit	3,405	4,028
Finance income	36	47
Finance costs	(45)	(69)
Profit before tax	3,396	4,007

Significant subsequent events

Not applicable.